OFFER: Technology for haemolysis detection

Hemcheck offers two free solutions for point-of-care testing

Hemcheck is offering two solutions to increase speed of blood testing in the clinical setting during the COVID-19 pandemic.

Both solutions use their unique concept, HELGE™ which detects haemolysis in blood samples in vacuum tubes and blood gas syringes during blood sampling at the point of care.

1. Informed and timely clinical decisions:

Given the critical situation with the outbreak and rapid spread of COVID-19 in society, HELGE™ could improve the flow of blood samples in clinical laboratories, emergency departments, infection clinics, intensive care units and ambulatory/mobile units. This, in turn, may decrease  turnaround times and overcrowding as well as reduce the workload of healthcare staff.

2. Testing in different settings:

The company’s second offer focuses on haemolysis detection in blood samples for SARS-CoV-2 antibody testing in different settings, such as mobile clinics or nursing homes.  HELGE^TM makes it possible to collect and test for haemolysis outside of a hospital setting, reducing the need for patients to travel during the pandemic.

HELGE™ consists of three parts; a disposable test for vacuum tubes (v-Test), a disposable test for blood gas syringes (s-Test) and a joint reader for reliable answers in 5-10 seconds. About 100 ul of the whole blood sample is inserted into the disposable test during blood collection. The single-use test separates plasma/serum in about one second. The test is then placed on the mobile reader (driven by a rechargeable battery) for measurement to define if the blood is haemolysed or not, given a predefined (adjustable) cut-off value, presented as a binary result through a red or green led indicator.

More information about the concept visit: https://hemcheck.com

Conditions of the offer:

• The offer is valid for three months
• The offer is will be subject to a separate and mutual agreement, with no ongoing obligation
• Hemcheck should be able to carry out training of healthcare and laboratory staff using the equipment via web link.
• Hemcheck should have the opportunity to evaluate the usage, for example through a simple user survey and/or follow up the effect on the heamolysis rate.
• The using department should have an interest in evaluating the product for a possible implementation in routine work after the trial period.
• Hemcheck cannot support too many hospitals at the same time due to capacity constraints so the offer is based on a first come, first served principle.

Hemcheck remains the right to decline requests that they are not able to accept and serve due to capacity constraints.